Vertex Pharmaceuticals Inc. (VRTX) शेयर — क्या यह अच्छा व्यवसाय है?

Vertex Pharmaceuticals Inc. (VRTX) शेयर — क्या यह अच्छा व्यवसाय है? — InspectStocks

कमाई कैसे होती है

TRIKAFTA/KAFTRIO sales75%
ALYFTREK sales17%
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI sales4%
CASGEVY sales2%
JOURNAVX sales2%

आमदनी के हिस्से quarter ended June 30, 2026 के अनुमान हैं, किसी दाख़िल रिपोर्ट के आँकड़े नहीं।

मुकाबला किनसे है

क्या बेचती है5

ALYFTREK
A once-daily combination medicine that improves the function of the faulty protein that causes cystic fibrosis.
TRIKAFTA/KAFTRIO
A combination medicine that improves the function of the faulty protein that causes cystic fibrosis. TRIKAFTA and KAFTRIO are brand names used in different markets.
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI
Other medicines for cystic fibrosis that improve the function of the protein involved in the disease.

2 और दिखाएँ

CASGEVY
A gene-editing treatment for severe sickle cell disease and transfusion-dependent beta thalassemia. A patient's blood-forming cells are collected, edited at a manufacturing facility, and returned for infusion.
JOURNAVX
An oral, non-opioid medicine for moderate-to-severe acute pain in adults.

कौन खरीदता है5

Specialty pharmacies and specialist distributors buy Vertex medicines and resell them to patients, pharmacies, health care providers, hospitals, or treatment centers.
Major wholesalers in the United States buy Vertex medicines for resale through pharmacies and health care providers.
Outside the United States, distributors, retail pharmacies, hospitals, and clinics buy or distribute medicines; some hospitals and clinics are government-owned or supported.

2 और दिखाएँ

Authorized treatment centers can receive CASGEVY directly from Vertex in some markets.
Government health programs and commercial insurers decide whether to cover medicines and reimburse purchases.

किस पर टिका है, और क्या इसे तोड़ सकता है

कारोबार किन चीज़ों पर टिका है

1The business depends substantially on cystic fibrosis medicines; sales therefore depend on continued patient use, access, and the medicines' ability to compete with other treatments.
2Vertex relies on outside manufacturers and suppliers for much of its commercial and clinical supply. CASGEVY also requires coordinated cell collection, editing, shipping, and treatment-center infusion.
3Sales depend on government programs and commercial insurers covering medicines and agreeing to reimbursement terms. The company also pays royalties on certain cystic fibrosis medicines and shares CASGEVY profits with CRISPR Therapeutics.

क्या ग़लत हो सकता है

1The company identifies its cystic fibrosis medicines as a substantial source of business dependence. Competing treatments, changes in patient use, or loss of patent protection could reduce sales.
2Vertex's future products depend on clinical trials showing acceptable safety and benefit and on regulators approving them. A delay or failure in programs such as povetacicept, inaxaplin, or zimislecel could limit its ability to add new medicines.
3The company relies on complex supply chains, outside manufacturers, and treatment-center coordination, particularly for cell and gene therapies. Manufacturing or distribution problems could delay or interrupt supply.

पूरे वित्तीय विवरण →

Vertex Pharmaceuticals Inc. के बारे में

Vertex discovers, tests, manufactures, and sells prescription medicines. Its approved medicines treat cystic fibrosis, severe sickle cell disease, transfusion-dependent beta thalassemia, and moderate-to-severe acute pain; it is also testing treatments for kidney disease, type 1 diabetes, and other conditions. It sells mainly through specialty pharmacies, distributors, and wholesalers, with some gene therapy supplied directly to treatment centers.

मुख्यालय: Boston, Massachusetts
स्थापना: 1989
कर्मचारी: 6,400 (December 31, 2025, high)
सूचीबद्ध: NASDAQ
वित्त वर्ष का अंत: December 31

Vertex Pharmaceuticals Inc. की अपनी रिपोर्टों से बना, जो अमेरिकी प्रतिभूति और विनिमय आयोग (SEC) में दाखिल की गईं। आँकड़े जैसे बताए गए, और प्रति-शेयर इतिहास आज के शेयर आधार पर पुनर्गणित। यह एक व्यवसाय का वर्णन है — यह निवेश सलाह नहीं है और न ही कुछ खरीदने या बेचने की सिफ़ारिश।

Keep exploring

The themes Vertex Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

कमाई कैसे होती है

TRIKAFTA/KAFTRIO sales75%
ALYFTREK sales17%
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI sales4%
CASGEVY sales2%
JOURNAVX sales2%

मुकाबला किनसे है

क्या बेचती है5

ALYFTREK
A once-daily combination medicine that improves the function of the faulty protein that causes cystic fibrosis.
TRIKAFTA/KAFTRIO
A combination medicine that improves the function of the faulty protein that causes cystic fibrosis. TRIKAFTA and KAFTRIO are brand names used in different markets.
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI
Other medicines for cystic fibrosis that improve the function of the protein involved in the disease.

2 और दिखाएँ

CASGEVY
A gene-editing treatment for severe sickle cell disease and transfusion-dependent beta thalassemia. A patient's blood-forming cells are collected, edited at a manufacturing facility, and returned for infusion.
JOURNAVX
An oral, non-opioid medicine for moderate-to-severe acute pain in adults.

कौन खरीदता है5

Specialty pharmacies and specialist distributors buy Vertex medicines and resell them to patients, pharmacies, health care providers, hospitals, or treatment centers.
Major wholesalers in the United States buy Vertex medicines for resale through pharmacies and health care providers.
Outside the United States, distributors, retail pharmacies, hospitals, and clinics buy or distribute medicines; some hospitals and clinics are government-owned or supported.

2 और दिखाएँ

Authorized treatment centers can receive CASGEVY directly from Vertex in some markets.
Government health programs and commercial insurers decide whether to cover medicines and reimburse purchases.

किस पर टिका है, और क्या इसे तोड़ सकता है

कारोबार किन चीज़ों पर टिका है

1The business depends substantially on cystic fibrosis medicines; sales therefore depend on continued patient use, access, and the medicines' ability to compete with other treatments.
2Vertex relies on outside manufacturers and suppliers for much of its commercial and clinical supply. CASGEVY also requires coordinated cell collection, editing, shipping, and treatment-center infusion.
3Sales depend on government programs and commercial insurers covering medicines and agreeing to reimbursement terms. The company also pays royalties on certain cystic fibrosis medicines and shares CASGEVY profits with CRISPR Therapeutics.

क्या ग़लत हो सकता है

1The company identifies its cystic fibrosis medicines as a substantial source of business dependence. Competing treatments, changes in patient use, or loss of patent protection could reduce sales.
2Vertex's future products depend on clinical trials showing acceptable safety and benefit and on regulators approving them. A delay or failure in programs such as povetacicept, inaxaplin, or zimislecel could limit its ability to add new medicines.
3The company relies on complex supply chains, outside manufacturers, and treatment-center coordination, particularly for cell and gene therapies. Manufacturing or distribution problems could delay or interrupt supply.

पूरे वित्तीय विवरण →

Vertex Pharmaceuticals Inc. के बारे में

मुख्यालय: Boston, Massachusetts
स्थापना: 1989
कर्मचारी: 6,400 (December 31, 2025, high)
सूचीबद्ध: NASDAQ
वित्त वर्ष का अंत: December 31

कमाई कैसे होती है

मुकाबला किनसे है

क्या बेचती है5

कौन खरीदता है5

किस पर टिका है, और क्या इसे तोड़ सकता है

कारोबार किन चीज़ों पर टिका है

क्या ग़लत हो सकता है

Vertex Pharmaceuticals Inc. के बारे में

Keep exploring

The theme it is part of

Highest-graded in Biotechnology

Grade rose recently in Healthcare

कमाई कैसे होती है

मुकाबला किनसे है

क्या बेचती है5

कौन खरीदता है5

किस पर टिका है, और क्या इसे तोड़ सकता है

कारोबार किन चीज़ों पर टिका है

क्या ग़लत हो सकता है

Vertex Pharmaceuticals Inc. के बारे में

Vertex Pharmaceuticals Inc.

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Keep exploring

The theme it is part of

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Biotech

वृद्धि और नकदी — 5 में से 4

कारोबार का रुझान

समय के साथ शेयर भाव और ग्रेड

कमाई कैसे होती है

मुकाबला किनसे है

क्या बेचती है5

कौन खरीदता है5

किस पर टिका है, और क्या इसे तोड़ सकता है

कारोबार किन चीज़ों पर टिका है

क्या ग़लत हो सकता है

Vertex Pharmaceuticals Inc. के बारे में

Keep exploring

The theme it is part of

Highest-graded in Biotechnology

Grade rose recently in Healthcare

कमाई कैसे होती है

मुकाबला किनसे है

क्या बेचती है5

कौन खरीदता है5

किस पर टिका है, और क्या इसे तोड़ सकता है

कारोबार किन चीज़ों पर टिका है

क्या ग़लत हो सकता है

Vertex Pharmaceuticals Inc. के बारे में

Vertex Pharmaceuticals Inc.

पिछला प्रदर्शन

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Keep exploring

The theme it is part of

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Biotech

वृद्धि और नकदी — 5 में से 4

कारोबार का रुझान

समय के साथ शेयर भाव और ग्रेड